<DOC>
	<DOCNO>NCT01209585</DOCNO>
	<brief_summary>The purpose study study evaluation blood sample blood type identify functional protein joint .</brief_summary>
	<brief_title>A Study Evaluate BioMarkers Blood Samples Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description>Assessment type I IFN signature peripheral blood activation type I IFN signal pathway synovial fluid ( indicate expression functional IFN protein joint ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Age 18 75 year time screen . Written inform consent locally require authorization ( eg , HIPAA USA ) , obtain subject prior performing protocolrelated procedure , include screen evaluation . A diagnosis : ) Adult onset RA define 1987 ACR classification criterion ( see Appendix 1 ) , least 4 tender 4 swollen joint screen ( Day 1 ) . Tender/swollen joint must part 28joint count include Disease Assessment Score 28 ( DAS28 ) assessment ; b ) Osteoarthritis ( OA ) knee acute pseudogout attack knee . Age ≥ 16 year time onset RA onset OA , pseudogout . Subjects either receive oral corticosteroid , receive oral corticosteroid , need stable dose oral prednisone ( equivalent ) ≤ 10 mg/day least 4 week prior screen ( Day 1 ) . Ability willingness complete study Day 120 require protocol . History current inflammatory joint disease RA , OA , pseudogout ( eg , gout , reactive arthritis , psoriatic arthritis , seronegative spondyloarthropathy , Lyme disease ) autoimmune disorder ( systemic lupus erythematosus , inflammatory bowel disease , scleroderma , inflammatory myopathy , overlap syndrome ) . Any neurological ( congenital acquire ) , psychiatric , vascular , systemic disorder could also affect evaluation disease assessment ; particular , joint pain swell . Treatment IFNα IFNβ . Intraarticular , IM , IV corticosteroid injection within 28 day screen ( Day 1 ) . Known history positive test result human immunodeficiency virus ( HIV ) . Serious infection ( eg , pneumonia , septicemia ) within 2 month prior Day 1 visit . Active bacterial viral infection ( include ongoing and/or chronic infection hepatitis , tuberculosis , etc ) . Concomitant use systemic antiviral , antibiotic , antifungal treatment active infection within 28 day Day 1 . History malignancy evidence active suspect malignancy ( exception adequately treat basal cell carcinoma skin situ carcinoma uterine cervix &gt; 1 year randomization study ) . Vaccinations within 4 week Day 1 visit . Concurrent enrollment another clinical study . Employees clinical study site individual involve conduct study , immediate family member individual . Other unspecified reason , opinion Investigator medical monitor , make subject unsuitable participation confound data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>